Diagnosis of autoimmune liver disease can be challenging. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune hepatitis, primary biliary cholangitis (PBC), and liver disease of unknown etiology.

"The disease spectrum is broad, and disease boundaries may be blurred by overlapping features," Dr. Tebo says. "The panel should ideally be requested following observation of abnormal liver enzymes, as well as for the elimination of common causes of liver disease such as metabolic, genetic, viral, drug, or alcohol-induced hepatitis."

The assay includes tests for two types of antibodies associated with autoimmune hepatitis and one type that is highly suggestive of PBC. Test results should be interpreted in the context of clinical assessment.

"Detection of these antibodies in asymptomatic patients may suggest risk for future disease development, which would require close monitoring for disease onset," Dr. Tebo says.

Listen to learn more about Mayo Clinic Laboratories' ALDG2 assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ALDG2   | Autoimmune Liver Disease Panel, Serum

Useful information

Evaluating patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cholangitis.

Evaluating patients with liver disease of unknown etiology.

Specimen requirements

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Performance information

• Analytic time: 3 - 4 days
• Day(s) and time(s) performed: Monday through Saturday

The latest

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

Noninvasive plasma biomarker testing provides faster answers: Alicia Algeciras-Schimnich, Ph.D. 

April 9, 2024

Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.

View MoreView Less